Recorded product revenue of $196.8 million and $634.0 million for the fourth quarter and full year, respectively,

representing a 96.6% and 105.3% increase from $100.1 million and $308.9 million in the prior year periods

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--$BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the fourth quarter and full year of 2021, recent business highlights, and anticipated upcoming milestones.

�Last year was transformative for our company, and we have built strategic competitive advantages that will help BeiGene to achieve our mission of making innovative medicines more readily accessible and affordable for all who need them. We have significantly increased the reach of our medicines, as BRUKINSA is now approved in 45 markets, and we now have 16 approved medicines in China, including our sixth approved indication for tislelizumab and five approved Novartis Oncology products in designated regions of China that we plan to promote following the transition from Novartis,� said John V. Oyler, Co-Founder, Chairman and Chief Executive Officer of BeiGene. �With exciting momentum for BRUKINSA including acceptance by the FDA and EMA of our supplemental NDAs for CLL, the most common form of adult leukemia, we are building a strong portfolio with cornerstone assets that will support the development of potential future new therapies. In addition, we have expanded our productive collaboration with Novartis by entering into an option, collaboration and license agreement to accelerate our anti-TIGIT antibody, ociperlimab, which is one of the most advanced assets in its class.�

Julia Wang, Chief Financial Officer, commented, �We are strongly positioned financially in an environment where the cost of capital is rising for our industry. In 2021, we added over $4 billion to our balance sheet through our public offering and new listing on the STAR market and the upfront payment from our collaboration with Novartis for tislelizumab, plus an additional $300 million in early 2022 for our TIGIT collaboration, that validates the strength of our research and development. Our commercial team is generating substantial product revenue from our internal and partnered medicines, and we expect revenue to continue to grow meaningfully in the year ahead based on approvals achieved and upcoming catalysts. We remain committed to building our internal clinical development and manufacturing capabilities that offer cost advantages and managing our expenses with discipline.�

Fourth Quarter and Full Year 2021 Financial Results

Cash, Cash Equivalents, Restricted Cash and Short-Term Investments were $6.62 billion as of December 31, 2021, compared to $3.92 billion as of September 30, 2021, and $4.66 billion as of December 31, 2020. Cash and cash equivalents as of December 31, 2021 do not include the $300 million upfront payment from Novartis for the ociperlimab option, collaboration and license agreement, which was received in January 2022.

• For the fourth quarter of 2021, total cash and short-term investments increased $2.7 billion; cash used in operating activities was $507.8 million; capital expenditures were $115.0 million; and cash provided from financing activities was $3.4 billion, almost entirely due to the net proceeds from the STAR Market offering on December 15, 2021.

• For the full year 2021, total cash and short-term investments increased $2.0 billion; cash used in operating activities was $1.3 billion; capital expenditures were $262.9 million; and cash provided from financing activities was $3.6 billion, primarily due to the net proceeds from the STAR Market offering on December 15, 2021.

Revenue for the fourth quarter and full year 2021 was $214.0 million and $1.2 billion, respectively, compared to $100.1 million and $308.9 million in the prior year periods. The increase in total revenue in the quarter compared to the prior year is attributable to sales of our internally developed products, sales of in-licensed products from Amgen and BMS, as well as collaboration revenue from the Novartis agreements.

• Product revenues totaled $196.8 million and $634.0 million for the fourth quarter and full year 2021, respectively, compared to $100.1 million and $308.9 million in the prior year periods, and were comprised of:

� Global sales of BRUKINSA of $87.6 million and $218.0 million for the fourth quarter and full year 2021, respectively, compared to $18.3 million and $41.7 million in the prior year periods. Full year 2020 revenue from BRUKINSA reflects sales since its launch in China in June 2020, as well as sales in the United States for the full year;

� Sales of tislelizumab in China of $54.4 million and $255.1 million for the fourth quarter and full year 2021, respectively, compared to $63.5 million and $163.4 million in the prior year periods. Sales of tislelizumab in the fourth quarter were impacted by 2022 National Reimbursement Drug List (NRDL) price reductions, which resulted in a negative adjustment of $25.4 million as a result of the normal process in China of compensating distributors for products previously sold at the 2021 price during the quarter that remained in the distribution channel. Full year 2021 sales of tislelizumab included two negative adjustments totaling $45.6 million for distributor channel inventory compensation as a result of inclusion in the March 2021 and January 2022 NRDL lists. Full year 2020 revenue from tislelizumab reflects sales since its launch in China in March 2020;

� Sales of BMS in-licensed products in China of $29.9 million and $89.7 million for the fourth quarter and full year 2021, respectively, compared to $12.6 million and $95.1 million in the prior year periods, respectively; and

� Sales of Amgen in-licensed products in China of $20.3 million and $58.8 million for the fourth quarter and full year 2021, respectively, compared to $5.4 million and $8.5 million in the prior year periods. We began selling Amgen's XGEVA� (denosumab) and BLINCYTO� (blinatumomab) in July 2020 and August 2021, respectively.

• Collaboration revenue totaled $17.2 million and $542.3 million for the fourth quarter and full year 2021, resulting from the partial recognition of the upfront payments from Novartis of $650.0 million related to the tislelizumab agreement and $300.0 million related to the ociperlimab agreement, which were entered into in the first and fourth quarters of 2021, respectively. We had no collaboration revenue in 2020.

Expenses for the fourth quarter and full year 2021 were $785.7 million and $2.6 billion, respectively, compared to $585.0 million and $2.0 billion in the prior year periods.

• Cost of Sales for the fourth quarter and full year 2021 were $48.5 million and $164.9 million, respectively, compared to $21.1 million and $70.7 million in the prior year periods. Cost of sales increased primarily due to increased product sales of tislelizumab, BRUKINSA and XGEVA, as well as sales of BLINCYTO, which commenced in August 2021.

• R&D Expenses for the fourth quarter and full year 2021 were $430.5 million and $1.5 billion, respectively, compared to $355.5 million and $1.3 billion in the prior year periods. The increase in R&D expenses was primarily attributable to increases in headcount and costs related to investment in our discovery and development activities, including our continued efforts to internalize research and clinical development activities, partially offset by lower fees paid to external CROs on clinical trials for BRUKINSA, tislelizumab and pamiparib, as well as decreased expense related to upfront fees for in-process R&D. Upfront fees related to in-process R&D for in-licensed assets totaled $30.0 million and $83.5 million in the fourth quarter and full year 2021, respectively, compared to nil and $109.5 million in the prior year periods. Employee share-based compensation expense also contributed to the overall increase in R&D expenses and was $30.6 million and $114.4 million for the fourth quarter and full year 2021, respectively, compared to $23.5 million and $93.0 million in the prior year periods, due to increased headcount and a higher share price.

• SG&A Expenses for the fourth quarter and full year 2021 were $306.5 million and $990.1 million, respectively, compared to $208.2 million and $600.2 million in the prior year periods. The increase in SG&A expenses was primarily attributable to increased headcount, largely related to continued expansion of our commercial teams, higher professional service fees and higher external commercial expenses, including selling and marketing, market access studies and promotional activities. The overall increase in SG&A expenses was also attributable to higher SG&A-related share-based compensation expense, which was $32.4 million and $126.4 million for the fourth quarter and full year 2021, respectively, compared to $26.0 million and $90.5 million for the prior year periods, due to increased headcount and a higher share price.

• Net Loss for the fourth quarter and full year 2021 was $585.7 million and $1.4 billion, or $0.47 and $1.17 per share, respectively, or $6.16 and $15.23 per ADS, respectively, compared to $472.7 million and $1.6 billion, or $0.40 and $1.47 per share, or $5.20 and $19.13 per ADS, respectively, in the prior year periods.

Recent Business Highlights

Commercial Operations

• Product sales increased 96.6% and 105.3% in the fourth quarter and full year of 2021 compared to the prior year periods, primarily due to increased sales of our internally developed products and in-licensed products from Amgen;
• Global sales of BRUKINSA totaled $87.6 million and $218.0 million in the fourth quarter and full year 2021, representing 378% and 423% increases compared to the prior year periods; U.S. sales of BRUKINSA totaled $55.9 million and $115.7 million in the fourth quarter and full year 2021, representing growth of 539% and 535%, compared to the prior year periods. U.S. sales continued to accelerate in the quarter, driven by continued uptake in mantle cell lymphoma (MCL) and the recent FDA approvals in Waldenstr�m�s macroglobulinemia (WM) and marginal zone lymphoma (MZL). BRUKINSA sales in China totaled $30.6 million and $101.2 million in the fourth quarter and full year 2021, representing growth of 219% and 331% compared to the prior year periods, driven by a significant increase in all approved indications, including chronic lymphocytic leukemia (CLL). Fourth quarter and full year 2021 sales of BRUKINSA in China were negatively impacted by accrued compensation to distributors of $4.4 million and $7.9 million, respectively, due to price changes related to BRUKINSA�s inclusion in the March 2021 and January 2022 NRDL lists;
• Sales of tislelizumab in China totaled $54.4 million and $255.1 million in the fourth quarter and full year 2021, representing a decline of 14% and growth of 56% compared to the prior year periods. In the fourth quarter, new patient demand from broader reimbursement and further expansion of our salesforce and hospital listings continued to drive increased market penetration and market share for tislelizumab;
• Continued to build commercial capabilities in designated regions of China referred to as Broad Markets to accommodate increasing medical demand. Our new agreement with Novartis granting us rights to market and promote five Novartis approved and nationally reimbursed oncology products expands our portfolio and enables our commercial team to reach patients in the Broad Markets with these medicines. These products include: TAFINLAR^� (dabrafenib), MEKINIST^� (trametinib), VOTRIENT^� (pazopanib), AFINITOR^� (everolimus), and ZYKADIA^� (ceritinib);
• Secured NRDL inclusion in China for our eligible medicines, including tislelizumab in first-line non-squamous non-small cell lung cancer (NSCLC), first-line squamous NSCLC and second- or third-line hepatocellular carcinoma (HCC), BRUKINSA in WM, and pamiparib in germline in patients with BRCA (gBRCA) mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy; and
• Our commercial organization in China continued to demonstrate its ability to bring new products to market, launching QARZIBA and POBEVCY in the fourth quarter.

Development Programs

BRUKINSA^� (zanubrutinib), a small molecule inhibitor of Bruton�s tyrosine kinase (BTK) designed to maximize BTK occupancy and minimize off-target effects, approved in 45 markets including the U.S., China, European Union (EU), Great Britain, Canada, and Australia in selected indications and under development for additional approvals globally. The global BRUKINSA development program includes nearly 4,000 subjects enrolled to-date in more than 25 countries and regions.

• Announced acceptance by the U.S. FDA of a supplemental new drug application for the treatment of adult patients with CLL or small lymphocytic lymphoma (SLL) based on data from two pivotal randomized Phase 3 studies ALPINE (NCT03734016) and SEQUOIA (NCT03336333) presented at the 26th European Hematology Association (EHA2021) Virtual Congress in June 2021 and at the 63rd American Society for Hematology (ASH) Annual Meeting in December 2021, respectively. The Prescription Drug User Fee Act (PDUFA) target action date is October 22, 2022;
• Announced acceptance by the European Medicines Agency of two marketing authorization applications for the treatment of patients with CLL and MZL;
• Received approval in South Korea for the treatment of adult patients with MCL who have received at least one prior therapy, and for the treatment of adult patients with WM who have received at least one prior therapy;
• Received approval in the EU for the treatment of adult patients with WM who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy. The approval is applicable to all 27 EU member states, plus Iceland, Liechtenstein and Norway. BeiGene has begun launching BRUKINSA in the EU;
• Received approvals for WM in Great Britain and Switzerland, and new approvals for MCL in Saudi Arabia and Ecuador, as well as new indication approval for MZL in Canada, and national reimbursement coverage for patients with WM in Israel. There are currently more than 40 marketing authorization applications in multiple indications under review around the world;
• Included in the National Comprehensive Cancer Network^� (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines^� version 2.2022) for patients with both CLL/SLL as a Category 2A preferred treatment option in the first- and second-line, for patients with and without del(17p)/TP53 mutation. BRUKINSA is not approved in CLL/SLL outside of China; and
• Announced acceptance of supplemental new drug applications (sNDA) in China as a treatment for adult patients with WM, and as a treatment for adult patients with CLL or SLL with breakthrough therapy designation (BTD).

Tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages; approved in China in selected indications and under development for additional approvals globally. The global tislelizumab clinical development program includes more than 9,000 subjects enrolled to-date in more than 35 countries and regions.

• Received approval in China in a sixth indication, for second- or third-line treatment of locally advanced or metastatic NSCLC;
• Announced positive findings from the global Phase 3 RATIONALE 305 trial (NCT03777657) versus placebo in combination with chemotherapy as a first-line treatment for patients with locally advanced, unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with PD-L1 expression. At the interim analysis, tislelizumab in combination with chemotherapy met the primary endpoint of overall survival (OS) in patients with PD-L1 expression, with additional follow-up needed to assess OS benefits in the intention-to-treat (ITT) population. The safety profile of tislelizumab was consistent with that observed in previous trials, with no new safety signals identified with the addition of chemotherapy; and
• Presented results from the Phase 3 RATIONALE 309 trial (NCT03924986) of tislelizumab in first-line patients with nasopharyngeal cancer at the European Society for Medical Oncology Immuno-Oncology Congress 2021. The trial significantly prolonged progression-free survival for patients and demonstrated a safety profile consistent with known risks of each treatment agent.

Ociperlimab (BGB-A1217), an investigational anti-TIGIT monoclonal antibody with competent Fc function. The global ociperlimab development program includes approximately 800 subjects enrolled to-date in 25 countries and regions.

• Announced an option, collaboration, and license agreement with Novartis to develop, manufacture and commercialize ociperlimab in North America, Europe, and Japan. BeiGene received an upfront payment of $300 million and granted Novartis an exclusive time-based option until late 2023 under which BeiGene would receive an additional payment of $600 or $700 million upon exercise of the option, subject to receipt of required antitrust approval. During the option period, Novartis will conduct and fund additional global clinical trials of ociperlimab in combination with tislelizumab in selected tumor types; and
• Initiated patient enrollment in BeiGene�s global Phase 2 AdvanTIG-205 trial (NCT05014815) in frontline stage IV NSCLC.

Early Stage Programs

• Continued to advance our early stage clinical pipeline of internally-developed product candidates at dose escalation stage, including BGB-A445 (an investigational non-ligand competing OX40 monoclonal antibody as monotherapy or in combination with tislelizumab in solid tumors), BGB-15025 (an investigational hematopoietic progenitor kinase 1 (HPK1) inhibitor as monotherapy or in combination with tislelizumab in solid tumors), and BGB-10188 (an investigational PI3K? inhibitor as monotherapy or in combination with BRUKINSA in hematology malignancies, or in combination with tislelizumab in solid tumors); and
• Initiated the first Phase 1 clinical trial (NCT05093270) of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor being developed for inflammation and immunology.

Collaboration with Amgen

• Launched KYPROLIS^� (carfilzomib) for injection, a next-generation proteasome inhibitor, in China for patients with R/R multiple myeloma.

Other Collaboration Programs

• Received approval and launched POBEVCY^� (a biosimilar to bevacizumab) in China, licensed from Bio-Thera Solutions, Ltd., for the treatment of patients with advanced, metastatic or recurrent NSCLC and metastatic colorectal cancer;
• Received approval in China of SYLVANT� (siltuximab for injection), licensed from EUSA Pharma (UK), Ltd., for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD);
• Launched QARZIBA^� (dinutuximab beta) in China, a targeted immunotherapy licensed from EUSA Pharma, for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of R/R neuroblastoma with or without residual disease; and
• Entered a worldwide license and collaboration agreement with Nanjing Leads Biolabs, Co., Ltd. (Leads Biolabs), for research, development and manufacturing rights and exclusive commercialization rights outside of China to LBL-007, a novel investigational antibody targeting the LAG-3 pathway.

Zanidatamab, an investigational bispecific antibody targeting HER2 in late-stage clinical development with Zymeworks Inc.

• Received Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for treating patients with biliary tract cancer who have failed prior systemic therapies; and
• Initiated the global Phase 3 HERIZON?GEA?01 clinical trial (NCT05152147) of zanidatamab plus chemotherapy, with or without tislelizumab, versus standard of care (trastuzumab plus chemotherapy), for the first-line treatment of metastatic HER2?positive gastroesophageal adenocarcinoma (GEA).

Corporate Developments

• Completed the public offering and initial listing of our ordinary shares on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange under the stock code �688235� with net proceeds of approximately US$3.4 billion;
• Held a grand opening ceremony for the BeiGene Bioisland Innovation Center (BIC) in Guangzhou, China to support scientists and entrepreneurs in accelerating the development of highly differentiated, cutting-edge medical innovations. The BIC is an innovator-centric incubator built on BeiGene�s goal of supporting exploration of new paths to meet patient needs around the world;
• Announced the appointment of Drs. Margaret Dugan and Alessandro Riva to our Board of Directors and the resignation of Sam Su from our Board after almost four years of service; and
• Expanded our Executive Committee with the following new leaders:

� Mark Lanasa, M.D., Senior Vice President, Chief Medical Officer, Solid Tumor;

� Kyu-Sung (�Q�) Lee, Senior Vice President, Global Head of Technical Operations and Manufacturing

� Kevin Mannix, Senior Vice President, Investor Relations;

� Jurij Petrin, Head of New Market Development; and

� Eva Yin, Chief Commercial Officer, Greater China.

Manufacturing Operations

• Closed on the acquisition of a 42-acre site at the Princeton West Innovation Campus in Hopewell, N.J., which BeiGene plans to develop as a new commercial-stage manufacturing and clinical R&D campus. Construction of the initial phase is expected to commence in 2022. In addition, the property has more than one million square feet of developable real estate for potential future expansion;
• Continued construction on the new small molecule manufacturing campus in Suzhou, China. Phase 1 of construction will bring over 52,000 square meters and 600M solid oral dosage capacity and is expected to be completed in 2023. Once completed, qualified, and approved, the total production capacity is expected to increase BeiGene's small molecule manufacturing capability in China by up to six times the current capacity; and
• Continued construction on the state-of-the-art biologics facility in Guangzhou, China, which currently is approved for 8,000 liters of biologics capacity, with an additional phase of construction to bring total capacity to 64,000 liters expected to be completed and GMP-ready by the end of 2022.

Expected Milestones

BRUKINSA

• Announce updated topline results for the Phase 3 ALPINE trial (NCT03734016) in R/R CLL/SLL in the second quarter of 2022;
• Announce clinical data from the global Phase 2 ROSEWOOD trial (NCT03332017) in R/R follicular lymphoma in 2022;
• Continue to support ongoing FDA review of the sNDA submission for CLL/SLL, which has a PDUFA target action date of October 22, 2022;
• Continue to support the EMA review of new indication applications for CLL and MZL; and
• Continue to expand BRUKINSA�s registration program globally in new geographies and indications, including potential launches in 2022 in more than 10 markets.

Contacts

Investors
Kevin Mannix

+1 857-302-5189

[email protected]

Media
Emily Collins

+1 201-201-4570

[email protected]

Read full story here